30 years of second-generation antiseizure medications: impact and future perspectives
Publication date: Available online 25 February 2020Source: The Lancet NeurologyAuthor(s): Emilio Perucca, Martin J Brodie, Patrick Kwan, Torbjörn Tomson (Source: The Lancet Neurology)
Source: The Lancet Neurology - February 27, 2020 Category: Neurology Source Type: research

Have new antiseizure medications improved clinical care over the past 30 years?
Publication date: Available online 25 February 2020Source: The Lancet NeurologyAuthor(s): Jacqueline A French, Robert T Wechsler (Source: The Lancet Neurology)
Source: The Lancet Neurology - February 27, 2020 Category: Neurology Source Type: research

Leading the way for neuromuscular disorders since 1950
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): The Lancet Neurology (Source: The Lancet Neurology)
Source: The Lancet Neurology - February 19, 2020 Category: Neurology Source Type: research

Issues important to the design of stroke recovery trials
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Steven C Cramer (Source: The Lancet Neurology)
Source: The Lancet Neurology - February 19, 2020 Category: Neurology Source Type: research

The need for continued care after sponsor closure
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Arne May (Source: The Lancet Neurology)
Source: The Lancet Neurology - February 19, 2020 Category: Neurology Source Type: research

The need for continued care after sponsor closure – Authors' reply
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Peter J Goadsby, Ali R Rezai, David W Dodick (Source: The Lancet Neurology)
Source: The Lancet Neurology - February 19, 2020 Category: Neurology Source Type: research

Health-care disparities for people with multiple sclerosis
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Joanna Laurson-Doube, Nick Rijke, Kathleen Costello, Jennifer McDonell, Gavin Giovannoni, Brenda Banwell, Peer Baneke (Source: The Lancet Neurology)
Source: The Lancet Neurology - February 19, 2020 Category: Neurology Source Type: research

Osmotherapy in traumatic brain injury
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Matthew J Rowland, Tonny Veenith, Peter J Hutchinson, Gavin D Perkins, SOS Trial Investigators (Source: The Lancet Neurology)
Source: The Lancet Neurology - February 19, 2020 Category: Neurology Source Type: research

Correction to Lancet Neurol 2020; 19: 38–48
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): (Source: The Lancet Neurology)
Source: The Lancet Neurology - February 19, 2020 Category: Neurology Source Type: research

Correction to Lancet Neurol 2020; 19: 247–54
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): (Source: The Lancet Neurology)
Source: The Lancet Neurology - February 19, 2020 Category: Neurology Source Type: research

Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Hugues Chabriat, Claudio L Bassetti, Ute Marx, Marie-Laure Audoli-Inthavong, Aurore Sors, Estelle Lambert, Marine Wattez, Dirk M Hermann, Katharina ALTHAUS, Sergi AMARO, Hee-Joon BAE, Zbigniew BAK, Leonardo BARBARINI, Pietro BASSI, Rodrigo BAZAN, Daniel BERECZKI, Tomasz BERKOWICZ, Joerg BERROUSCHOT, Dylan BLACQUIERE, Waldemar BROLASummaryBackgroundS44819, a selective GABAA α5 receptor antagonist, reduces tonic post-ischaemic inhibition of the peri-infarct cortex. S44819 improved stroke recovery in rodents and increased cortical exc...
Source: The Lancet Neurology - February 19, 2020 Category: Neurology Source Type: research

Patient-reported outcome measures: the need for new and reliable tools
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Ankur Khajuria (Source: The Lancet Neurology)
Source: The Lancet Neurology - February 19, 2020 Category: Neurology Source Type: research

Long-term unsupervised mobility assessment in movement disorders
Publication date: Available online 11 February 2020Source: The Lancet NeurologyAuthor(s): Elke Warmerdam, Jeffrey M Hausdorff, Arash Atrsaei, Yuhan Zhou, Anat Mirelman, Kamiar Aminian, Alberto J Espay, Clint Hansen, Luc J W Evers, Andreas Keller, Claudine Lamoth, Andrea Pilotto, Lynn Rochester, Gerhard Schmidt, Bastiaan R Bloem, Walter MaetzlerSummaryMobile health technologies (wearable, portable, body-fixed sensors, or domestic-integrated devices) that quantify mobility in unsupervised, daily living environments are emerging as complementary clinical assessments. Data collected in these ecologically valid, patient-relevan...
Source: The Lancet Neurology - February 12, 2020 Category: Neurology Source Type: research

Wearable-based mobility monitoring: the long road ahead
Publication date: Available online 11 February 2020Source: The Lancet NeurologyAuthor(s): Alfonso Fasano, Martina Mancini (Source: The Lancet Neurology)
Source: The Lancet Neurology - February 12, 2020 Category: Neurology Source Type: research

Advances in oral immunomodulating therapies in relapsing multiple sclerosis
Publication date: Available online 11 February 2020Source: The Lancet NeurologyAuthor(s): Tobias Derfuss, Matthias Mehling, Athina Papadopoulou, Amit Bar-Or, Jeffrey A Cohen, Ludwig KapposSummaryBackgroundOral treatment options for disease-modifying therapy in relapsing multiple sclerosis have substantially increased over the past decade with four approved oral compounds now available: fingolimod, dimethyl fumarate, teriflunomide, and cladribine. Although these immunomodulating therapies are all orally administered, and thus convenient for patients, they have different modes of action. These distinct mechanisms of action a...
Source: The Lancet Neurology - February 12, 2020 Category: Neurology Source Type: research

Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study
In this study, we aimed to determine the frequency and distribution of paediatric demyelinating and encephalitic syndromes with MOG antibodies, their response to treatment, and the phenotypes associated with poor prognosis.MethodsIn this prospective observational study, children with demyelinating syndromes and with encephalitis other than acute disseminated encephalomyelitis (ADEM) recruited from 40 secondary and tertiary centres in Spain were investigated for MOG antibodies. All MOG antibody-positive cases were included in our study, which assessed syndromes, treatment and response to treatment (ie, number of relapses), ...
Source: The Lancet Neurology - February 11, 2020 Category: Neurology Source Type: research

Breaking boundaries between demyelinating disorders and autoimmune encephalitis
Publication date: Available online 10 February 2020Source: The Lancet NeurologyAuthor(s): Romain Marignier (Source: The Lancet Neurology)
Source: The Lancet Neurology - February 11, 2020 Category: Neurology Source Type: research

Advances and challenges in stroke rehabilitation
Publication date: Available online 28 January 2020Source: The Lancet NeurologyAuthor(s): Cathy M Stinear, Catherine E Lang, Steven Zeiler, Winston D ByblowSummaryStroke remains a leading cause of adult disability and the demand for stroke rehabilitation services is growing. Substantial advances are yet to be made in stroke rehabilitation practice to meet this demand and improve patient outcomes relative to current care. Several large intervention trials targeting motor recovery report that participants' motor performance improved, but to a similar extent for both the intervention and control groups in most trials. These ne...
Source: The Lancet Neurology - January 30, 2020 Category: Neurology Source Type: research

β-adrenoreceptors and the risk of Parkinson's disease
Publication date: Available online 27 January 2020Source: The Lancet NeurologyAuthor(s): Franziska Hopfner, Günter U Höglinger, Gregor Kuhlenbäumer, Anton Pottegård, Mette Wod, Kaare Christensen, Caroline M Tanner, Günther DeuschlSummaryBackgroundβ-adrenoceptors are widely expressed in different human organs, mediate important body functions and are targeted by medications for various diseases (such as coronary heart disease and heart attack) and many β-adrenoceptor acting drugs are listed on the WHO Model List of Essential Medicines. β-adrenoceptor antagonists are used by billions ...
Source: The Lancet Neurology - January 28, 2020 Category: Neurology Source Type: research

Interpretation of risk loci from genome-wide association studies of Alzheimer's disease
Publication date: Available online 24 January 2020Source: The Lancet NeurologyAuthor(s): Shea J Andrews, Brian Fulton-Howard, Alison GoateSummaryBackgroundAlzheimer's disease is a debilitating and highly heritable neurological condition. As such, genetic studies have sought to understand the genetic architecture of Alzheimer's disease since the 1990s, with successively larger genome-wide association studies (GWAS) and meta-analyses. These studies started with a small sample size of 1086 individuals in 2007, which was able to identify only the APOE locus. In 2013, the International Genomics of Alzheimer's Project (IGAP) did...
Source: The Lancet Neurology - January 25, 2020 Category: Neurology Source Type: research

Feast or famine in multiple sclerosis therapeutics
Publication date: Available online 22 January 2020Source: The Lancet NeurologyAuthor(s): Robert J Fox (Source: The Lancet Neurology)
Source: The Lancet Neurology - January 24, 2020 Category: Neurology Source Type: research

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
Publication date: Available online 22 January 2020Source: The Lancet NeurologyAuthor(s): Jeremy Chataway, Floriana De Angelis, Peter Connick, Richard A Parker, Domenico Plantone, Anisha Doshi, Nevin John, Jonathan Stutters, David MacManus, Ferran Prados Carrasco, Frederik Barkhof, Sebastien Ourselin, Marie Braisher, Moira Ross, Gina Cranswick, Sue H Pavitt, Gavin Giovannoni, Claudia Angela Gandini Wheeler-Kingshott, Clive Hawkins, Basil SharrackSummaryBackgroundNeurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical re...
Source: The Lancet Neurology - January 24, 2020 Category: Neurology Source Type: research

Publication records versus scientific progress
Publication date: February 2020Source: The Lancet Neurology, Volume 19, Issue 2Author(s): The Lancet Neurology (Source: The Lancet Neurology)
Source: The Lancet Neurology - January 22, 2020 Category: Neurology Source Type: research

Research participation for patients with spinal cord injury
Publication date: February 2020Source: The Lancet Neurology, Volume 19, Issue 2Author(s): Annemie Heselmans (Source: The Lancet Neurology)
Source: The Lancet Neurology - January 22, 2020 Category: Neurology Source Type: research

Correction to Lancet Neurol 2018; 17: 597–608
Publication date: February 2020Source: The Lancet Neurology, Volume 19, Issue 2Author(s): (Source: The Lancet Neurology)
Source: The Lancet Neurology - January 22, 2020 Category: Neurology Source Type: research

Correction to Lancet Neurol 2019; 18: 1078–79
Publication date: February 2020Source: The Lancet Neurology, Volume 19, Issue 2Author(s): (Source: The Lancet Neurology)
Source: The Lancet Neurology - January 22, 2020 Category: Neurology Source Type: research

Correction to Lancet Neurol 2020; 19: 106–08
Publication date: February 2020Source: The Lancet Neurology, Volume 19, Issue 2Author(s): (Source: The Lancet Neurology)
Source: The Lancet Neurology - January 22, 2020 Category: Neurology Source Type: research

Correction to Lancet Neurol 2020; 19: 145–56
Publication date: February 2020Source: The Lancet Neurology, Volume 19, Issue 2Author(s): (Source: The Lancet Neurology)
Source: The Lancet Neurology - January 22, 2020 Category: Neurology Source Type: research

Subjective cognitive decline: what is it good for?
Publication date: Available online 17 January 2020Source: The Lancet NeurologyAuthor(s): Robert Howard (Source: The Lancet Neurology)
Source: The Lancet Neurology - January 19, 2020 Category: Neurology Source Type: research

The characterisation of subjective cognitive decline
Publication date: Available online 17 January 2020Source: The Lancet NeurologyAuthor(s): Frank Jessen, Rebecca E Amariglio, Rachel F Buckley, Wiesje M van der Flier, Ying Han, José Luis Molinuevo, Laura Rabin, Dorene M Rentz, Octavio Rodriguez-Gomez, Andrew J Saykin, Sietske A M Sikkes, Colette M Smart, Steffen Wolfsgruber, Michael WagnerSummaryA growing awareness about brain health and Alzheimer's disease in the general population is leading to an increasing number of cognitively unimpaired individuals, who are concerned that they have reduced cognitive function, to approach the medical system for help. The term su...
Source: The Lancet Neurology - January 19, 2020 Category: Neurology Source Type: research

Continual Raving: A History of Meningitis and the People Who Conquered It, Janet R Gilsdorf. Oxford University Press (2019), 264, £22.99, ISBN: 9780190677312
Publication date: Available online 10 January 2020Source: The Lancet NeurologyAuthor(s): Eelco Wijdicks (Source: The Lancet Neurology)
Source: The Lancet Neurology - January 12, 2020 Category: Neurology Source Type: research

Correction to Lancet Neurol 2019; 18: 653–65
Publication date: Available online 3 January 2020Source: The Lancet NeurologyAuthor(s): (Source: The Lancet Neurology)
Source: The Lancet Neurology - January 4, 2020 Category: Neurology Source Type: research

Long-term safety and efficacy of closed-loop spinal cord stimulation to treat chronic back and leg pain (Evoke): a double-blind, randomised, controlled trial
This study is registered with ClinicalTrials.gov, NCT02924129, and is ongoing.FindingsBetween Feb 21, 2017, and Feb 20, 2018, 134 patients were enrolled and randomly assigned (67 to each treatment group). The intention-to-treat analysis comprised 125 patients at 3 months (62 in the closed-loop group and 63 in the open-loop group) and 118 patients at 12 months (59 in the closed-loop group and 59 in the open-loop group). The primary outcome was achieved in a greater proportion of patients in the closed-loop group than in the open-loop group at 3 months (51 [82·3%] of 62 patients vs 38 [60·3%] of 63 patients; di...
Source: The Lancet Neurology - December 21, 2019 Category: Neurology Source Type: research

Personalising pain control with spinal cord stimulation
Publication date: Available online 20 December 2019Source: The Lancet NeurologyAuthor(s): Bizhan Aarabi (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 21, 2019 Category: Neurology Source Type: research

A cornerstone initiative for progress in Parkinson's disease
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): The Lancet Neurology (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Stroke research in 2019: towards optimising treatment and prevention
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): Simiao Wu, Yajun Cheng, Bo Wu, Ming Liu (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Research momentum brings hope for dementia in 2019
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): Julie Schneider (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Traumatic brain injury in 2019: databases, biomarkers, and stratified treatment
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): Junfeng Feng, Jiyao Jiang (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Emerging treatments for headache: advances in 2019
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): Gisela M Terwindt (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Unravelling the heterogeneity of epilepsy for optimal individualised treatment: advances in 2019
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): Page B Pennell (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Movement disorders in 2019: from antibodies to lifestyle interventions
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): Claudia Trenkwalder, Brit Mollenhauer (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Multiple sclerosis in 2019: predicting progression
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): Alexis A Lizarraga, Bianca Weinstock-Guttman (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Important advances in neuromuscular research in 2019
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): Vera Bril (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Advances in sleep medicine in 2019
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): Swapan Dholakia, Nancy Collop (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Neurological infections in 2019: challenges, solutions, and open questions
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): Uwe Koedel, Matthias Klein, Hans Walter Pfister (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Emerging concepts in neuroscience research: 2019 highlights
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): Patrizia Casaccia (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Preclinical Alzheimer's disease: a valid concept
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): Clifford R Jack (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Neuromyelitis optica in patients with increased interferon alpha concentrations
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): Jac Williams, Sarah McGlasson, Sarosh Irani, Darragh Duffy, Yanick Crow, David Hunt, Murray Katy, Wilson Robert, Jackson Andrew P, Jury Alexa, Rodero Mathieu, Bondet Vincent, Jacob Anu, Hamid Shahd, Cordeiro Nuno, Dolezal Ondrej, Statham Patrick, Wiseman Stewart, Wardlaw Joanna, Hertel Christina (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Correction to Lancet Neurol 2019; 18: 1103–11
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research

Correction to Lancet Neurol 2020; 19: 23–24
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): (Source: The Lancet Neurology)
Source: The Lancet Neurology - December 12, 2019 Category: Neurology Source Type: research